|Page (1) of 1 - 09/03/13||email article||print page|
This morning, Leerink Swann increased its price target on shares of Pfizer (PFE) to $28.50 as international sales of Lyrica could boost earnings at the pharmaceutical giant. In the report, Leerink increased its EPS estimates and maintained its market perform rating.
|Analyst Moves: PFE, VZ, MU|
Source:GrabNetworks (c). All Rights Reserved